<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30096">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895517</url>
  </required_header>
  <id_info>
    <org_study_id>TRIUC1312</org_study_id>
    <secondary_id>UMIN000010843</secondary_id>
    <nct_id>NCT01895517</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of Co-testing Liquid-based Cytology ( LBC) and HPV DNA Testing for the Primary Cervical Cancer Screening</brief_title>
  <official_title>Randomized Controlled Trial to Evaluate the Efficacy of Concurrent Liquid-based Cytology ( LBC) and HPV DNA Testing Versus LBC Alone for the Primary Cervical Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Informatics Center, Kobe, Hyogo, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Keio University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jikei University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Research Informatics Center, Kobe, Hyogo, Japan</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess efficacy of the screening with concurrent liquid-based
      cytology and HPV DNA testing for the primary cervical cancer screening over 7 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening</study_design>
  <primary_outcome>
    <measure>The incidence of cervical intraepithelial neoplasia(CIN)3 or worse during the whole period</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of CIN3 or worse at baseline, and two years, four years, and six years post baseline</measure>
    <time_frame>2 years, 4 years, 6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of CIN2 or worse at baseline, and two years, four years, and six years post baseline</measure>
    <time_frame>2 years, 4 years, 6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of CIN1 or worse at baseline, and two years, four years, and six years post baseline</measure>
    <time_frame>2 years, 4 years, 6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of invasive cancer at baseline, and two years, four years, and six years post baseline</measure>
    <time_frame>2 years, 4 years, 6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of cervical cytology performance</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of colposcopy and biopsy performance</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>LBC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cervical cancer screening by using liquid based cytology as a standard screening modality</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LBC plus HPV DNA testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LBC</intervention_name>
    <description>Cervical cancer screening by using liquid based cytology as a standard screening modality</description>
    <arm_group_label>LBC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LBC plus HPV DNA testing</intervention_name>
    <description>Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality</description>
    <arm_group_label>LBC plus HPV DNA testing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women aged 30-64 years old

          2. Participants provided written informed consent

        Exclusion Criteria:

        Women who

          1. will receive planed HPV DNA testing by local governmental cervical cancer program
             next six years

          2. have had cervical invasive cancer before

          3. have undergone cervical conization

          4. have undergone hysterectomy

          5. have had or have the cytological abnormalities and are under follow-up

          6. are pregnant

          7. are judged ineligible for this trial by physician
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daisuke Aoki, M.D., Ph.D.</last_name>
    <phone>+81-3-3353-1211</phone>
    <email>aoki@z7.keio.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>School of Medicine, Keio University</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daisuke Aoki, M.D., Ph.D.</last_name>
      <phone>+81-3-3353-1211</phone>
      <email>aoki@z7.keio.jp</email>
    </contact>
    <investigator>
      <last_name>Daisuke Aoki, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 27, 2014</lastchanged_date>
  <firstreceived_date>July 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
